1. Home
  2. PSO vs ABVX Comparison

PSO vs ABVX Comparison

Compare PSO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pearson Plc

PSO

Pearson Plc

N/A

Current Price

$13.13

Market Cap

8.2B

ML Signal

N/A

Logo Abivax SA American

ABVX

Abivax SA American

N/A

Current Price

$117.69

Market Cap

10.5B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PSO
ABVX
Founded
1844
2013
Country
United Kingdom
France
Employees
17116
67
Industry
Books
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
10.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PSO
ABVX
Price
$13.13
$117.69
Analyst Decision
Strong Buy
Buy
Analyst Count
1
12
Target Price
N/A
$128.42
AVG Volume (30 Days)
994.3K
698.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.48%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.90
N/A
Revenue Next Year
$4.88
$0.22
P/E Ratio
$14.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.02
$4.77
52 Week High
$16.70
$148.83

Technical Indicators

Market Signals
Indicator
PSO
ABVX
Relative Strength Index (RSI) 55.15 49.76
Support Level $12.92 $106.37
Resistance Level $13.34 $131.27
Average True Range (ATR) 0.23 5.21
MACD 0.06 -0.62
Stochastic Oscillator 74.12 44.88

Price Performance

Historical Comparison
PSO
ABVX

About PSO Pearson Plc

UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualification testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: